Eiffel to raise $3 million

By Renate Krelle
Friday, 06 August, 2004

Shares in Sydney drug re-engineering company Eiffel Technologies (ASX: EIF) slumped today when the company announced a capital raising of AUD$3.0 million, placing 36.4 million fully paid ordinary shares at 8.25 cents per share.

A proportion of the placement will be subject to approval at an extraordinary general meeting. The balance, of approximately 14 per cent of the company's capital, will be issued immediately. The placement was supported by existing shareholders and new institutional investors.

In a statement, the company said it plans to use the funds for manufacturing, screening of further re-engineered drugs, pre-clinical studies and patent applications. It will also explore the potential to acquire additional re-engineering technology platforms and complementary drug delivery technologies.

Shares were down 10 per cent to 8.8 cents at time of writing.

Related News

Preventing neural graft rejection in Parkinson's patients

Researchers have engineered a way to fool the immune system into accepting neural grafts as part...

Retinal health linked to dementia risk, study shows

Researchers have discovered that the blood vessels at the back of the eye — called retinal...

Pancreatic cancer hijacks metabolism switch to help it spread

Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd